PTJ
KRYS icon

Paul Tudor Jones’s Krystal Biotech KRYS Stock Holding History

Paul Tudor Jones’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-14,476
Closed -$3.74M – 3947
2026
Q1 		$3.74M Buy
14,476
+13,101
+953% +$3.49M 0.01% 1374
2025
Q4 		$339K Buy
+1,375
New +$289K ﹤0.01% 2963
2022
Q4 		– Sell
-11,546
Closed -$805K – 2642
2022
Q3 		$805K Buy
+11,546
New +$834K 0.02% 1066
2022
Q1 		– Sell
-12,562
Closed -$879K – 2375
2021
Q4 		$879K Buy
+12,562
New +$731K 0.01% 1090

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Paul Tudor Jones's KRYS Position: Q2 2026 in Review

Paul Tudor Jones sold out of Krystal Biotech (KRYS) in Q2 2026, closing a stake of 14,476 shares — an estimated $3.74M sold.

Paul Tudor Jones first reported a position in KRYS in Q4 2021 and held it in 4 quarters. The position peaked at $3.74M in Q1 2026. 420 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Paul Tudor Jones reported no remaining Krystal Biotech position as of Q2 2026 after selling out during the quarter.
  • Paul Tudor Jones sold 14,476 Krystal Biotech shares in Q2 2026, an estimated $3.74M.
  • Paul Tudor Jones first reported a position in Krystal Biotech in Q4 2021 and held it in 4 quarters.
  • Paul Tudor Jones's Krystal Biotech position peaked at $3.74M in Q1 2026.
  • 420 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.